Business Context and Reporting Period
Company: BioDrain Medical, Inc. (Note: Metadata listed "Axe Compute Inc." but the filing text identifies BioDrain Medical, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2011
Business Stage: Development stage company focused on an environmentally safe system for collecting and disposing of infectious fluids from surgical procedures (Fluid Management System or "FMS").
Regulatory Status: Received FDA 510(k) clearance on April 1, 2009. First billable shipment occurred in June 2009.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2011 | Six Months Ended June 30, 2010 |
|---|---|---|
| Revenue | $2,374 | $288 |
| Net Loss | $(864,819) | $(798,070) |
| Loss Per Share (Basic/Diluted) | $(0.04) | $(0.07) |
| Cash Balance (End of Period) | $57,638 | $8,834 |
| Accumulated Deficit | $(8,246,896) | $(7,382,077) |
| Total Assets | $250,565 | $165,872 |
| Total Liabilities | $2,690,022 | $2,355,429 |
| Shareholders' Deficit | $(2,439,358) | $(2,189,557) |
Debt Structure: Significant reliance on convertible debt. Current portion of convertible debt is $663,412 (net of discounts). Long-term debt and convertible debt total $660,218. Accounts payable stands at $731,857.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased to $2,374 from $288 in the prior six-month period, driven by sales of disposable supplies to a beta site customer.
- Expense Reductions: General and Administrative (G&A) expenses decreased significantly to $585,824 from $1,150,616. This was primarily due to a $467,000 reduction in stock-based consulting expense and a $67,000 reduction in salary expense (avoiding a termination settlement charge incurred in 2010).
- Operating Expenses: Operations expense increased to $267,121 from $109,659, attributed to increased manufacturing supplies and components for product adjustments.
- Debt Valuation Gains: The company recorded a gain of $190,915 on the revaluation of equity-linked financial instruments, compared to a gain of $676,414 in the prior period. The reduction in gain is due to a narrowing spread between warrant exercise prices and the underlying stock price.
- Liquidity: Cash on hand increased from $9,383 at year-end 2010 to $57,638 at June 30, 2011, supported by financing activities.
Outlook, Risks, and Management Commentary
Capital Needs and Liquidity: Management states that current cash reserves are sufficient only through approximately September 2011. The company requires approximately $2 million in new equity to operate for the next 12 months. A new investment banker was engaged in May 2011 to raise this capital. Failure to raise funds could force a reduction in operations or cessation of business.
Going Concern: The financial statements include a "substantial doubt" disclosure regarding the company's ability to continue as a going concern due to recurring losses and a shareholders' deficit.
Dilution Risk: Future equity financing is expected to result in substantial dilution to existing shareholders. The company has issued significant stock and warrants in connection with debt and equity financings.
Operational Outlook: The company expects operations expenses to increase as it prepares for commercial shipments of the FMS unit. Sales and marketing expenses are expected to rise significantly once funding is secured to hire additional personnel and attend trade shows.
Investor Verification Checklist
- Capital Runway: Verify the status of the $2 million fundraising effort initiated in May 2011, as the company projects cash exhaustion by September 2011.
- Debt Conversion Terms: Review the specific conversion formulas for the convertible debt (often based on the lowest trading prices over 10-day periods), which can lead to significant dilution.
- Revenue Sustainability: Assess whether the $2,374 in revenue represents a sustainable commercial trend or isolated beta-site sales.
- Related Party Transactions: Examine the notes regarding debt held by officers' parents and related party agreements for potential conflicts or preferential terms.
- Equity-Liabilities: Monitor the "Liability for equity-linked financial instruments" ($110,539), as fluctuations in stock price directly impact net income/loss through revaluation gains or losses.